In his weekly clinical update, Dr. Griffin reviews recent statistics on the circulation of respiratory syncytial virus before discussing uptake of the RSV vaccine Abrysvo or the monoclonal anti-RSV antibody nirsevimab to prevent severe disease following RSV infection in infants 8 months or younger before going over this week’s influenza virus and SARS-CoV-2 virus statistics, including all circulating variants in the US, examines if self-testing is more accurate than clinician administered Binax rapid diagnostic tests for SARS-CoV-2 infection, if N95 masks need a yearly fitting, how SARS-CoV-2 vaccination impacts the prevalence of long COVID, reviews the CDC guidelines for quarantine/ isolation following SARS-CoV-2 infection, continues to dispel the myth of viral rebound, how to pay for paxlovid, when to use steroids and the benefits of convalescent plasma, why determining the exact number of long COVID incidences is challenging, how the incidence and predictors for fatiguing illness following SARS-CoV-2 infection may used to reenforce the need for public health actions to prevent virus infection and the risks of respiratory pathologies including lung cancer associate with SARS-C0V-2 infection.

In his weekly clinical update, Dr. Griffin discusses the use of monoclonal antibody therapy to prevent RSV hospitalization of infants and use of GSK’s RSV vaccine Arexy to prevent severe disease following RSV infection in adults between 50-59 years before he reviews recent statistics on the circulation of respiratory syncytial virus, influenza virus and SARS-CoV-2 virus, including all circulating variants in the US, discusses if how the influenza vaccine is manufactured can reprogram the antibody response, cardiovascular consequences of influenza infection, mortality of chikungunya virus infection, if an alternative vaccination schedule impacts the anti-SARS-CoV-2 immune response, dispels the myth that increased mortality correlated with the first vaccine dose, continues to dispel the myth of viral rebound, how to pay for paxlovid, when to use steroids and the benefits of convalescent plasma, how manage long COVID including prevent burnout and compassion fatigue of caring for long COVID patients, whether the CDC or WHO definition of long COVID is beneficial or the use of directed questions, baselines test and listening to the patient tell their story are beneficial in making a long COVID diagnosis.

In his weekly clinical update, Dr. Griffin discusses the how the pandemic influenced the healthcare job market and why people conceal their infectious diseases before he reviews most recent statistics on the circulation of respiratory syncytial virus, influenza virus and SARS-CoV-2 virus, including all circulating variants in the US, discusses if susceptibility and disease severity are inheritable traits, if vaccination during pregnancy protects neonates or leads to adverse effects, the effectiveness of a monovalent XBB.1.5 against disease resulting from infection with Omicron variants, whether vaccination in the same or opposite arms effect antibody protection, continues to dispel the myth of viral rebound, how to pay for paxlovid, when to use steroids and the benefits of convalescent plasma, how SARS-CoV-2 infection may alter one’s sleep patterns, what the health and economic burdens of mild disease are, and if there are predictors for recovery from fatigue and cognitive deficits following SARS-CoV-2 infection.

In his weekly clinical update, Dr. Griffin discusses the how the pandemic influenced the healthcare job market before he reviews most recent statistics on the circulation of respiratory syncytial virus, influenza virus and SARS-CoV-2 virus, including all circulating variants in the US, discusses the safety of the prefusion RSV vaccine, if high or moderate dose of the quadrivalent influenza vaccine is better for protection against hospitalization, summarizes the new WHO COVID guidelines, revisits how to prevent pathogen transmission in healthcare setting, the under use of COVID oral antiviral and what occurs in persistently SARS-CoV-2 infected cells in culture after antiviral treatment, continues to dispel the myth of viral rebound, how to pay for paxlovid, when to use steroids and the benefits of convalescent plasma, how inflammatory markers change correlate with death when in ICU and if cognitive slowing is part of long COVID-19.

In his weekly clinical update, Dr. Griffin reviews most recent statistics on the circulation of respiratory syncytial virus, influenza virus and SARS-CoV-2 virus, including all circulating variants in the US, before discussing viral transmission to adults in healthcare setting, the recently EUA approved protein based COBREVAX vaccine, reviews quarantine guidelines, the use of simnotrelivr for mild to moderate COVID-19, how viral RNA may persist in your cell culture dish following antiviral therapy, continues to dispel the myth of viral rebound, how to pay for Paxlovid, , when to use steroids and the benefits of convalescent plasma, how Paxlovid may prevent long COVID and how complement dysfunction may lead to thromboinflammation during long COVID.

In his weekly clinical update, Dr. Griffin reviews most recent statistics on the circulation of respiratory syncytial virus, influenza virus and SARS-CoV-2 virus in the US before discussing vaccine effectiveness in children and adolescents, how the pandemic impacted the socioemotional development of infants and toddlers, continues to dispel the myth of viral rebound, how to pay for Paxlovid, reviews quarantine guidelines, when to use steroids and the benefits of convalescent plasma, examines the role of immune aberrations in long COVID and how vaccination may protect against developing long COVID.

In his weekly clinical update, Dr. Griffin reviews recent measles outbreaks, prequalification of nOPV2 by the WHO and most recent statistics on the circulation of respiratory syncytial virus, influenza virus and SARS-CoV-2 virus in the US before discussing COVID-19 deaths linked to SNPs in C-reactive protein, spread of recent viral variants, how early vaccination reduced hospitalization of those infected with XBB.1.5, reviewed quarantine guidelines, how oral antivirals reduce hospitalizations, dissociation of antiviral treatment from infection rebound, and long COVID, deaths due to administration of hydroxychloroquine, muscle abnormalities and extreme fatigue in individuals with long COVID-19 and how the economics of where you live make long COVID-19 more severe.

Vincent travels to McGill University in Montreal, Canada to join Angela for a discussion of the careers and the research of two faculty members, Corinne Maurice and Jesse Shapiro, and their PhD trainees Anshul Sinha and Sana Naderi.

In his weekly clinical update, Dr. Griffin highlights global circulation of Mpox virus, reviews the most recent statistics on the circulation of respiratory syncytial virus, influenza virus and SARS-CoV-2 virus in the US, and discusses the clinical outcome of hospitalized children under 5 years infected with SARS-CoV-2, the perinatal and neonatal outcomes including adverse effects of SARS-CoV-2 infection and virus transmission in Italy between early 2020 and 2022, the guidelines to improve home ventilation, the safety and efficacy of the oral anti-viral molnupiravir and the use of convalescent plasma as a long term treatment as well as treatment specifically for the immune compromised, the ineffectiveness of antibiotics for treating COVID-19, the association of olfactory dysfunction and the administration of corticosteroids and the safety of the RSV vaccines licensed last year.